Article Details

EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments

Retrieved on: 2024-06-21 22:47:30

Tags for this article:

Click the tags to see associated articles and topics

EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments. View article details on hiswai:

Summary

The article summarizes various Phase I-III clinical trials on multiple myeloma (MM) presented at the EHA 2024 congress. It links epidemiological data to these studies, showcasing promising treatments involving orphan drugs like isatuximab, bortezomib, lenalidomide, and others, improving outcomes for MM patients.

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up